213 (PB201): MYC Inhibition by OMO-103 Reprograms Tumor Immunity and Enhances Immunotherapy Efficacy in KRAS Mutant NSCLC

Serra, S. Casacuberta; González-Larreategui, Íñigo; Vera, Laura; Adradas, Vera; Martínez-Martín, S.; Peressini, Melina; López-Estévez, S.; Arnal, Magdalena; San‐Segundo, Laura; Pozo, E. Serrano del; Grueso, J.; Foradada, Laia; Thabussot, H.; Giuntini, F.; Whitfield, J.; Beaulieu, M.E.; Zugazagoitia, J.; Vicent, S.; Soucek, Laura

doi:10.1016/j.ejca.2024.114731

European Journal of Cancer

2024

DOI: 10.1016/j.ejca.2024.114731

|Get access via publisher |Cite

213 (PB201): MYC Inhibition by OMO-103 Reprograms Tumor Immunity and Enhances Immunotherapy Efficacy in KRAS Mutant NSCLC

S. Casacuberta Serra¹,

Íñigo González-Larreategui²,

Laura Vera³

et al.

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles

Scite is an AI-powered research tool that helps researchers better discover and evaluate scientific literature through Smart Citations—a revolutionary system that shows whether articles support, contrast, or simply mention a given claim. Founded in 2018, and now part of Research Solutions, Scite has indexed over 1.3 billion citations and partnered with more than 30 major publishers to provide researchers with unparalleled access to scientific literature. With its Scite Assistant, Smart Citation Index, and advanced search capabilities, the platform addresses critical challenges such as information overload and research reproducibility. Trusted by two million active users worldwide, Scite is reshaping how researchers interact with scholarly content—building ethical, transparent AI tools that support rigorous, copyright-compliant research.